Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
Dr Jörg Spiekerkötter is a member of PAION’s Supervisory Board since June 2007. Dr Jörg Spiekerkötter has many years of experience in the pharmaceutical industry where he has held executive positions in the areas of finance, law and human resources. Until May 2007, he was the Chief Financial Officer of Organon BioSciences N.V., Oss (Netherlands). He left after the acquisition of the company by the US pharmaceutical company Schering-Plough. Until September 2006, he was the Chief Financial Officer at Schering AG in Berlin (Germany), and before that Head of the Legal Department at Hoechst Schering AgrEvo GmbH in Berlin (Germany). Dr Spiekerkötter studied in Bielefeld (Germany), Lausanne (Switzerland) and Freiburg (Germany) and has a Ph.D. in law. Until December 2010, he was the Chief Financial Officer of Conergy AG, Hamburg (Germany). On 19 May 2010, PAION’s Supervisory Board appointed Dr Spiekerkötter as its Chairman.
Dr Karin Dorrepaal, member of PAION’s Supervisory Board since October 2012. She has broad experience in the Life Science Industry. Between 2004 and 2006, she was a member of the Management Board of Schering AG in Berlin. From 1990 to 2004 she worked as management consultant at Booz Allen & Hamilton in Amsterdam and New York. From 1985 until 1988 she was a Ph. D. Research Fellow at The Netherlands Cancer Institute in Amsterdam. .
John Dawson is a member of PAION’s Supervisory Board since May 2014. He is Chief Executive Officer of Oxford BioMedica. From 1996 to 2007 he held senior management positions in the European operations of Cephalon Inc., including from 2005, a management board position as Chief Financial Officer and Head of Business Development Europe. In his time at Cephalon he led many of the deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to a turnover of several hundred million US dollars. In 2005 he led the US$360 million acquisition of Zeneus by Cephalon. Between 1991 and 1996 he was Director of Finance and Administration of Serono Laboratories (UK) Limited.
Dr. Dr. Irina Antonijevic is a member of PAION’s Supervisory Board since May 2017.
Dr. Dr. Irina Antonijevic joined vasopharm GmbH in 2016 as Chief Medical Officer. She has more than 16 years of drug development experience in different pharmaceutical organizations, with a focus on neuropsychiatric and rare diseases. In her last role at Sanofi Genzyme in Cambridge (MA, USA), she oversaw multiple innovative clinical programs as Global Head Early Development Neurology and Ophthalmology. She completed her medical studies at the Technical University of Munich (1991), received her MD from the Max Planck Institute in Munich (1992) and her PhD from the University of Edinburgh, UK (1995). She completed her residency at the Max Planck Institute of Psychiatry in Munich and received her Venia Legendi from the Charité, Berlin, in 2004. Dr. Dr. Antonijevic has been a regular reviewer for the German Ministry of Research (BMBF) since 2006.
Dr. Chris Tanner is a member of PAION’s Supervisory Board since May 2017.
Dr. Chris Tanner was a member of the Executive Board since 2005 and has been a member of the Supervisory Board of Cosmo Pharmaceuticals N.V. since 2006 for which he conducted the IPO as Chief Financial Officer and Head of Investor Relations. In 2015, Cosmo span off the daughter Cassiopea SpA where he also acts as Chief Financial Officer and Head of Investor Relations. Moreover, he is a member of the board of directors or advisory board (Beirat) of listed DKSH AG, Private Equity Holding AG and the private medtec companies Qvanteq AG and Joimax GmbH. From 1998 to 2001, he was a partner of Dr. Ernst Mueller-Moehl and co-founder of the 20 Minutes group of newspapers and founded A&A Active Investor, a SIX-listed investment company. From 1992 to 1998, he was the Head of Corporate Finance & Capital Markets at UBS in Zurich, and from 1976 to 1991 he had various functions in the Corporate Banking Department at UBS in Zurich, Madrid and Los Angeles. Dr. Tanner has a PhD in economics and a diploma as economist from the University of St. Gallen.